Skip to main navigation Skip to search Skip to main content

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study

  • Ailsa Hart
  • , Remo Panaccione
  • , Flavio Steinwurz
  • , Silvio Danese
  • , Tadakazu Hisamatsu
  • , Qian Cao
  • , Timothy Ritter
  • , Ursula Seidler
  • , Mobolaji Olurinde
  • , Marion L. Vetter
  • , Jacqueline Yee
  • , Zijiang Yang
  • , Yuhua Wang
  • , Jewel Johanns
  • , Chenglong Han
  • , Aparna Sahoo
  • , Natalie A. Terry
  • , Bruce E. Sands
  • , the GRAVITI Study Group
  • London North West University Healthcare NHS Trust
  • University of Calgary
  • Hospital Israelita Albert Einstein
  • Vita-Salute San Raffaele University
  • Kyorin University
  • Zhejiang University
  • GI Alliance Research
  • Hannover Medical School
  • Johnson & Johnson
  • Icahn School of Medicine at Mount Sinai
  • Amsterdam UMC - University of Amsterdam

Research output: Contribution to journal › Article › Academic › peer-review

37 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry